http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
AbbVie to Acquire Aliada Therapeutics, Strengthening Focus in Alzheimer's Disease and Neuroscience Pipeline
-
Independent Modeling Studies from MIT and SIA and Results from Previous Testing Presented at TopFuel 2024 Conference Further Validate that Lightbridge Fuel™ has Safety Advantages Over Current Nuclea
-
ReasonLabs Wins 2024 CyberSecurity Breakthrough Award For Online Security Platform
-
Banuba Enhances Virtual Hair Dye Try-On Technology for Unmatched Realism and Precision
-
Coinstar Launches Digital Wallet 'CINQ by Coinstar' to Expand Possibilities for Using and Managing Finances
-
U.S. Postal Service is Ready to Deliver the Nation's Election Mail
-
Toggle3D.AI Unveils AI Photo Studio SaaS with Scalable API Integration for Advanced Image Creation
-
Leading Supply-side Partners Including FreeWheel, Index Exchange, Magnite, Microsoft Monetize and PubMatic Integrate European Unified ID to Maintain Relevant Advertising
-
Zimmer Biomet Holdings (ZBH) to Debut New Z1 Femoral Hip System and Clinical Data on G7® Acetabular System at 2024 AAHKS Annual Meeting
-
George Mason University Team Develops Successful Augmented Reality Campus Tour for Transfer Students Using ARway.ai
-
Zimmer Biomet to Debut New Z1™ Femoral Hip System and Clinical Data on G7® Acetabular System at 2024 AAHKS Annual Meeting
-
Marqeta, Inc. (MQ) Announces Marqeta Flex, An Industry-Leading, Buy Now, Pay Later Solution That Can Be Embedded Into Payment Apps
-
Evoke Pharma (EVOK) and EVERSANA Announce Statistically Significant Improvement in Patient Outcomes for GLP-1 users
-
Thermal Energy Receives $1.5 Million Heat Recovery Order from a Multinational Confectionery Company
-
Evoke Pharma & EVERSANA Announce Statistically Significant Improvement in Patient Outcomes for GLP-1 users with Diabetic Gastroparesis using GIMOTI®
-
Hughes Electronically Steerable Antenna (ESA) Successfully Completes Flight Test Using LEO
-
Fractyl Health to Present Compelling Weight Maintenance Data from both Revita® and Rejuva® Platforms at ObesityWeek® 2024
-
Bitfarms Appoints Rachel Silverstein as U.S. General Counsel
-
Ideology Over Wallet: One Week from the Election, Small Business Owners Say They'll Vote First on Personal Ideals
-
Krystal Biotech to Report Third Quarter 2024 Financial Results on November 4, 2024
-
Cathedra Bitcoin Announces Partnership with Compass Mining
-
Odyssey Therapeutics and Terray Therapeutics Enter Strategic Collaboration to Jointly Discover and Develop First-in-Class Transcription Factor Therapies
-
Evoke Pharma & EVERSANA Announce Statistically Significant Improvement in Patient Outcomes for GLP-1 users with Diabetic Gastroparesis using GIMOTI®
-
Marqeta Announces Marqeta Flex, An Industry-Leading, Buy Now, Pay Later Solution That Can Be Embedded Into Payment Apps
-
Pluri Collaborates with Bar-Ilan University to Advance Cancer Immunotherapy for Solid Tumors, Supported by Israel Innovation Authority
-
Bristol Myers Squibb to Present New Clinical and Health Economics and Outcomes Research Data at Psych Congress 2024
-
Piedmont Lithium Announces Q3’24 North American Lithium Operational Results
-
Merck (MRK) and Moderna (MRNA) Initiate Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA
-
Merck and Moderna Initiate Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients With Certain Types
-
Elbit Systems (ESLT) Wins $200M Contract with the Israeli MOD to Supply High-Power Laser for the "Iron Beam" Air Defense System
-
BeiGene (BGNE) Announces Passing of Director Donald Glazer
-
BeiGene Mourns Death of Beloved Board Member Donald Glazer
-
Orchestra Grows Consumer, Experiential & Influencer Marketing Capabilities with Small Girls PR Acquisition
-
FDA Grants De Novo Marketing Authorization for the Distalmotion Dexter® Surgical Robot
-
Elbit Systems Awarded Approximately $200 Million Contract by the Israeli MOD to Supply High-Power Laser for the "Iron Beam" Air Defense System
-
Q2 Metals Drills 347.1 m at 1.35% Li2O Including 30 m at 1.76% Li2O at the Cisco Lithium Property, James Bay, Quebec, Canada
-
RETRANSMISSION: Cruz Announces Record Date of October 29th for Spin-Out of Hector Silver-Cobalt Project
-
HomeTown Health Honors Rural Healthcare Leaders & Partners in Georgia
-
Miscellaneous
-
JCDecaux has decided not to pursue the acquisition of Clear Channel’s business in Spain
-
Black & Veatch Introduces Hydrogen, Advisory and Broad Portfolio of Sustainable Energy Solutions at ADIPEC 2024
-
Lessons In Visionary Investments: Dr. Kingsley Chin's Journey with AxioMed Mirrors Elon Musk's Bold Bet on Tesla
-
Fineqia Announces Intention to Close Private Placement on Oct. 31, 2024
-
ACG Presidential Plenary to Highlight Analysis of Xifaxan(R) (rifaximin) Risk Reduction of Overt Hepatic Encephalopathy (OHE) Recurrence
-
Exact Sciences Presents Multiple Studies at ACG 2024 Demonstrating Leadership in Noninvasive Colorectal Cancer Screening and Patient Engagement
-
Odyssey Therapeutics to Present New Data on its Clinical-Stage RIPK2 Scaffolding Inhibitor, OD-07656, at the American College of Gastroenterology (ACG) Annual Scientific Meeting 2024
-
Novartis oral Fabhalta® (iptacopan) sustained clinically meaningful results at one year in Phase III C3 glomerulopathy (C3G) trial
-
Novartis oral Fabhalta® (iptacopan) sustained clinically meaningful results at one year in Phase III C3 glomerulopathy (C3G) trial
-
Pivotal VALIANT Results Presented at Kidney Week Highlight Strength of Pegcetacoplan Treatment Effect in Patients with C3G / Primary IC-MPGN
-
US labor board wrongly ordered Tesla's Musk to delete anti-union tweet, court rules
